The clinical experience of compassionate use program for avapritinib: implications for drug positioning in the therapeutic scenario of systemic mastocytosis

In systemic mastocytosis, cytoreductive treatment is indicated for advanced systemic mastocytosis (AdvSM) variants. The treatment scenario is rapidly diversifying especially with the introduction of KIT tyrosine kinase inhibitors. Avapritinib is a second-generation potent and selective inhibitor of...

Descripción completa

Detalles Bibliográficos
Autores principales: Mannelli, Francesco, Crupi, Francesca, Zanotti, Roberta, Pagano, Livio, Rapezzi, Davide, Tanasi, Ilaria, Criscuolo, Marianna, Bonifacio, Massimiliano, Fresa, Alberto, Guglielmelli, Paola, Vannucchi, Alessandro M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623899/
https://www.ncbi.nlm.nih.gov/pubmed/37929078
http://dx.doi.org/10.1177/20406207231205643

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10623899/
https://www.ncbi.nlm.nih.gov/pubmed/37929078
http://dx.doi.org/10.1177/20406207231205643

Ejemplares similares